Searched for
THERAPEUTIC
No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling caseThe Maharashtra government has assured the Bombay High Court it will halt raids and confiscations concerning ayurvedic product labels. This...- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- India slams Pakistan's 'trade and transit terrorism' and deadly Afghan airstrikes at UNSCAt the UN Security Council, India fiercely condemned Pakistan for blocking Afghan trade and launching deadly airstrikes that killed 372 civ...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.
- Psychology says people who still reread old group chats from years ago share these 3 emotional reflection patternsDiving into old group chats is like flipping through a scrapbook of memories, revealing pieces of the person we used to be. These digital i...
- Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...
- Hexagon Nutrition IPO Day 2: GMP signals 15% listing gain; Retail portion subscribed 2.43xHexagon Nutrition’s Rs 139 crore IPO saw strong retail demand on Day 2, with the retail portion subscribed 2.43 times. The grey market prem...
- Hexagon Nutrition IPO Day 1: 37% subscription, Grey market signals 27% listing gainHexagon Nutrition's IPO opened strongly on its first day. Retail investors showed significant interest, subscribing 62% of their quota. The...
- Sorry Gen Z, but knowing therapy words doesn't make you emotionally intelligentAs therapy-related language becomes increasingly common, many people are questioning whether knowing mental health terminology automaticall...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concernsThe Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approva...
- US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concernsThe oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and or...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Sir H.N. Reliance Foundation Hospital Claims Top Spot In Nationwide Critical Care SurveySir H.N. Reliance Foundation Hospital has been ranked the country's leading multi-specialty institution in the Times of India Critical Care...
- Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoYSupriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surgin...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
Load More
